Skip to main content

Table 3 Baseline clinical and biological characteristics of coagulopathic patients in the placebo and rFVIIa groups

From: Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials

  Placebo group (n = 76) rFVIIa group (n = 60)
Age (years) 34 ± 12 31 ± 11
Gender   
   Men 63 (83%) 51 (85%)
   Women 13 (17%) 9 (15%)
Type of trauma   
   Penetrating 38 (50%) 35 (58%)
   Blunt 38 (50%) 25 (42%)
Injury severity score 30 ± 13 30 ± 13
Number of body regions injured   
   1 16 (21%) 13 (22%)
   2–3 40 (53%) 29 (48%)
   >3 18 (24%) 17 (28%)
   Unknown 2 (3%) 1 (2%)
Systolic blood pressure (mm Hg) 103 ± 26 109 ± 31
Mean arterial pressure (mm Hg) 74 ± 22 78 ± 23
Body temperature (°C) 35.2 ± 1.6 35.6 ± 1.1
pH 7.27 ± 0.11 7.29 ± 0.10
Hematocrit (percentage) 23 ± 8 26 ± 7
aPTT (seconds) 54 ± 24 46 ± 26
PT (seconds) 20 ± 5 17 ± 7
Fibrinogen (g/l) 1.3 ± 0.8 1.4 ± 0.6
Platelets (× 109) 70 ± 42 87 ± 47
  1. Data are mean ± standard deviation or number (percentage). No significant statistical differences between groups were observed. aPTT, activated partial thromboplastin time; PT, prothrombin time; rFVIIa, recombinant activated factor VII.